<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Science and Innovations in Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Science and Innovations in Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Наука и инновации в медицине</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2500-1388</issn><issn publication-format="electronic">2618-754X</issn><publisher><publisher-name xml:lang="en">FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">702620</article-id><article-id pub-id-type="doi">10.35693/SIM702620</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original study articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Evaluation of the effect of ionizing radiation on the viability of prostate cancer cells under NEK2 gene knockdown</article-title><trans-title-group xml:lang="ru"><trans-title>Оценка влияния ионизирующего излучения на жизнеспособность клеток рака предстательной железы при нокдауне гена NEK2</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-2274-5508</contrib-id><name-alternatives><name xml:lang="en"><surname>Kazanchyan</surname><given-names>Razmik O.</given-names></name><name xml:lang="ru"><surname>Казанчян</surname><given-names>Размик Оганесович</given-names></name></name-alternatives><email>ro_kazanchyan@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3011-6904</contrib-id><name-alternatives><name xml:lang="en"><surname>Golovinov</surname><given-names>Igor V.</given-names></name><name xml:lang="ru"><surname>Головинов</surname><given-names>Игорь Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ivgolovinov@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3972-2452</contrib-id><name-alternatives><name xml:lang="en"><surname>Kaplieva</surname><given-names>Irina V.</given-names></name><name xml:lang="ru"><surname>Каплиева</surname><given-names>Ирина Викторовна</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, доцент, заведующий испытательным лабораторным центром</p></bio><email>kaplirina@yandex.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7823-3865</contrib-id><name-alternatives><name xml:lang="en"><surname>Galina</surname><given-names>Anastasia V.</given-names></name><name xml:lang="ru"><surname>Галина</surname><given-names>Анастасия Владимировна</given-names></name></name-alternatives><email>volkovaav58@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3753-4463</contrib-id><name-alternatives><name xml:lang="en"><surname>Khodakova</surname><given-names>Darya V.</given-names></name><name xml:lang="ru"><surname>Ходакова</surname><given-names>Дарья Владиславовна</given-names></name></name-alternatives><email>khodakovadv@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-1125-2897</contrib-id><name-alternatives><name xml:lang="en"><surname>Shulga</surname><given-names>Anna A.</given-names></name><name xml:lang="ru"><surname>Шульга</surname><given-names>Анна Александровна</given-names></name></name-alternatives><email>slip.anka96@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9747-8515</contrib-id><name-alternatives><name xml:lang="en"><surname>Gurova</surname><given-names>Sofia V.</given-names></name><name xml:lang="ru"><surname>Гурова</surname><given-names>Софья Валерьевна</given-names></name></name-alternatives><email>gurova.sophie@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9468-134X</contrib-id><name-alternatives><name xml:lang="en"><surname>Shevchenko</surname><given-names>Aleksey N.</given-names></name><name xml:lang="ru"><surname>Шевченко</surname><given-names>Алексей Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>onko-sekretar@mail.ru</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9348-4777</contrib-id><name-alternatives><name xml:lang="en"><surname>Vorobyova</surname><given-names>Ada V.</given-names></name><name xml:lang="ru"><surname>Воробьева</surname><given-names>Ада Валерьевна</given-names></name></name-alternatives><email>ada180699@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3289-8436</contrib-id><name-alternatives><name xml:lang="en"><surname>Vlasov</surname><given-names>Sergey N.</given-names></name><name xml:lang="ru"><surname>Власов</surname><given-names>Сергей Николаевич</given-names></name></name-alternatives><email>ser.vl4s0v02@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4680-8991</contrib-id><name-alternatives><name xml:lang="en"><surname>Vlasov</surname><given-names>Stanislav G.</given-names></name><name xml:lang="ru"><surname>Власов</surname><given-names>Станислав Григорьевич</given-names></name></name-alternatives><email>stasikvlasov1994rgmu@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><institution></institution></aff><aff-alternatives id="aff2"><aff><institution xml:lang="en">National Medical Research Centre for Oncology</institution></aff><aff><institution xml:lang="ru">ФГБУ «НМИЦ онкологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Rostov Research Institute of Oncology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Ростовский научно-исследовательский онкологический институт» Минздрава РФ</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">National Medical Research Centre for Oncology</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр онкологии</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2026-06-08" publication-format="electronic"><day>08</day><month>06</month><year>2026</year></pub-date><history><date date-type="received" iso-8601-date="2026-03-03"><day>03</day><month>03</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-04-19"><day>19</day><month>04</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; , Kazanchyan R.O., Golovinov I.V., Kaplieva I.V., Galina A.V., Khodakova D.V., Shulga A.A., Gurova S.V., Shevchenko A.N., Vorobyova A.V., Vlasov S.N., Vlasov S.G.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; , Казанчян Р.О., Головинов И.В., Каплиева И.В., Галина А.В., Ходакова Д.В., Шульга А.А., Гурова С.В., Шевченко А.Н., Воробьева А.В., Власов С.Н., Власов С.Г.</copyright-statement><copyright-holder xml:lang="en">Kazanchyan R.O., Golovinov I.V., Kaplieva I.V., Galina A.V., Khodakova D.V., Shulga A.A., Gurova S.V., Shevchenko A.N., Vorobyova A.V., Vlasov S.N., Vlasov S.G.</copyright-holder><copyright-holder xml:lang="ru">Казанчян Р.О., Головинов И.В., Каплиева И.В., Галина А.В., Ходакова Д.В., Шульга А.А., Гурова С.В., Шевченко А.Н., Воробьева А.В., Власов С.Н., Власов С.Г.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://innoscience.ru/2500-1388/article/view/702620">https://innoscience.ru/2500-1388/article/view/702620</self-uri><abstract xml:lang="en"><p><bold>Aim </bold>– to evaluate the antitumor effect of ionizing radiation on non-transfected and transfected (with <italic>NEK2</italic> gene knockdown) prostate cancer cell lines by analyzing their viability <italic>in vitro</italic>.</p> <p><bold>Material and methods. </bold>The study was performed using human prostate cancer cell lines PC-3 and DU145, as well as a primary culture of tumor cells (PCa-PC) obtained from a patient with acinar prostate adenocarcinoma (Gleason score 7: 4+3). <italic>NEK2</italic> gene knockdown was achieved by RNA interference using miRNA. Irradiation was carried out using a Theratron Equinox unit as a single dose of 6 Gy 48 h after transfection. Cell viability was assessed 24 h later by trypan blue staining. Results were expressed as percentages (M±SD). Radiosensitization was evaluated using the enhancement index (EI). Statistical analysis was performed using two-way analysis of variance (ANOVA) with Holm correction; a p&lt;0.05 was considered statistically significant.</p> <p><bold>Results.</bold> Irradiation without <italic>NEK2</italic> knockdown caused a moderate decrease in cell viability in PC-3 and PCa-PC cells, whereas no statistically significant effect was observed in the DU145 cell line. <italic>NEK2</italic> knockdown alone resulted in a pronounced reduction in cell viability in all studied cell lines (p&lt;0.0001). Combined treatment with ionizing radiation and <italic>NEK2</italic> knockdown produced the maximum cytotoxic effect, reducing cell viability by more than threefold compared with control. EI values exceeded 1 and ranged from 2.5 to 3.7 depending on the cell line.</p> <p><bold>Conclusion.</bold> Suppression of <italic>NEK2</italic> gene expression significantly reduces the viability of prostate cancer cells and increases their radiosensitivity, suggesting NEK2 as a promising molecular target for radiosensitization. The obtained results require further validation in in vivo models.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель </bold>– оценить противоопухолевое действие ионизирующего излучения на нетрансфицированные и трансфицированные (с нокдауном гена <italic>NEK2</italic>) клеточные линии РПЖ путём анализа их жизнеспособности <italic>in vitro</italic>.</p> <p><bold>Материал и методы.</bold> Исследование выполнено на клеточных линиях рака предстательной железы человека PC-3 и DU145, а также на первичной культуре опухолевых клеток (PCa-PC), полученной от пациента с ацинарной аденокарциномой предстательной железы (Gleason 7: 4+3). Нокдаун гена <italic>NEK2</italic> осуществляли методом РНК-интерференции с использованием миРНК. Облучение проводили на аппарате Theratron Equinox однократно в дозе 6 Гр через 48 ч после трансфекции. Жизнеспособность клеток оценивали через 24 ч методом окрашивания трипановым синим. Результаты выражали в процентах (M±SD). Радиосенсибилизацию определяли по индексу усиления (Enhancement Index, EI). Статистическую обработку данных выполняли с использованием двухфакторного дисперсионного анализа (ANOVA) с поправкой Холма; уровень значимости принимали равным p&lt;0,05.</p> <p><bold>Результаты.</bold> Облучение без нокдауна <italic>NEK2</italic> вызывало умеренное снижение жизнеспособности клеток PC-3 и PCa-PC, тогда как в линии DU145 статистически значимого эффекта не отмечено. Самостоятельное подавление экспрессии <italic>NEK2</italic> приводило к выраженному снижению жизнеспособности во всех исследованных линиях (p&lt;0,0001). Комбинированное воздействие ионизирующего излучения и нокдауна <italic>NEK2</italic> обеспечивало максимальный цитотоксический эффект с уменьшением жизнеспособности более чем в 3 раза по сравнению с контролем. Значения EI превышали 1 и достигали 2,5–3,7 в зависимости от клеточной линии.</p> <p><bold>Выводы.</bold> Подавление экспрессии гена <italic>NEK2</italic> существенно снижает жизнеспособность клеток рака предстательной железы и повышает их радиочувствительность, что позволяет рассматривать NEK2 как перспективную молекулярную мишень для радиосенсибилизации. Полученные данные требуют дальнейшей валидации в <italic>in vivo</italic>-моделях.</p></trans-abstract><kwd-group xml:lang="en"><kwd>tumor cell lines</kwd><kwd>radiosensitivity</kwd><kwd>rna interference</kwd><kwd>serine/threonine kinases</kwd><kwd>ionizing radiation</kwd><kwd>in vitro.</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>клеточные линии опухолей</kwd><kwd>радиочувствительность</kwd><kwd>рнк-интерференция</kwd><kwd>серин/треониновые киназы</kwd><kwd>ионизирующее излучение</kwd><kwd>in vitro.</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was the authors’ initiative without external funding.</funding-statement><funding-statement xml:lang="ru">Работа выполнена по инициативе авторов без привлечения финансирования.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Kit OI, Maksimova NA, Gusareva MA, et al. Intravenous radionuclide therapy with radium chloride [223Ra] in patients with bone metastases from castration-resistant prostate cancer. South Russian Journal of Cancer. 2024;5(4):6-13. (In Russ.). [Кит О.И., Максимова Н.А., Гусарева М.А., и др. Применение внутривенной радионуклидной терапии радия хлоридом [223Ra] у пациентов с костными метастазами кастрационно-резистентного рака предстательной железы. Южно-Российский онкологический журнал. 2024;5(4):6-13]. DOI: 10.37748/2686-9039-2024-5-4-1</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Buskin A, Scott E, Nelson R, et al. Engineering prostate cancer in vitro: what does it take? Oncogene. 2023;42(32):2417-2427. DOI: 10.1038/s41388-023-02776-6</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Zinkovich MS, Maksimov AY, Rozenko LY, et al. Radioresistance as a factor in the evolution of radiation therapy for prostate cancer. Modern problems of science and education. 2019;2:107. Available at: http://science-education.ru/ru/article/view?id=28627 (accessed 12 Feb 2026). (In Russ.) [Зинькович М.С., Максимов А.Ю., Розенко Л.Я. и др. Радиорезистентность как фактор эволюции лучевой терапии рака предстательной железы. Современные проблемы науки и образования. 2019;2:107.]</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Singh N, Heemers HV. Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications. Endocr Relat Cancer. 2023;30(9):e230011. DOI: 10.1530/ERC-23-0011</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Xu T, Zeng Y, Shi L, et al. Targeting NEK2 impairs oncogenesis and radioresistance via inhibiting the Wnt1/β-catenin signaling pathway in cervical cancer. J Exp Clin Cancer Res. 2020;39(1):183. DOI: 10.1186/s13046-020-01659-y</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kazanchyan RO, Golovinov IV, Kaplieva IV, et al. Evaluation of the impact of NEK2 gene knockdown on the viability and migration of prostate cancer cells. Modern problems of science and education. 2026;2. Available at: https://science-education.ru/ru/article/view?id=34467 (accessed 25 Feb 2026). (In Russ.) [Казанчян Р.О., Головинов И.В., Каплиева И.В. и др. Оценка влияния нокдауна гена NEK2 на жизнеспособность и миграцию клеток рака предстательной железы. Современные проблемы науки и образования. 2026;2.] DOI: 10.17513/spno.34467</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Pszczółkowska-Kępa B, Olejarz W, Głuszko A, et al. Exosome-mediated modulation of radioresistance: The radiation-induced bystander effect in prostate cancer cells. PLoS One. 2025;20(8):e0330501. DOI: 10.1371/journal.pone.0330501</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440-6. DOI: 10.1158/0008-5472.CAN-09-1947</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Field A. Discovering Statistics Using IBM SPSS Statistics. 5th ed. London: SAGE Publications Ltd; 2018. 1070 p. ISBN 978-1-5264-1951-4.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kyjacova L, Hubackova S, Krejcikova K, et al. Radiotherapy-induced plasticity of prostate cancer mobilizes stem-like non-adherent, Erk signaling-dependent cells. Cell Death Differ. 2015;22(6):898-911. DOI: 10.1038/cdd.2014.97</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Zeng YR, Han ZD, Wang C, et al. Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer. BMC Urol. 2015;15:90. DOI: 10.1186/s12894-015-0085-7</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Gu S, Yasen Y, Wang M, et al. NEK2 promotes the migration, invasion, proliferation of ESCC and mediates ESCC immunotherapy. Heliyon. 2024;10(9):e29682. DOI: 10.1016/j.heliyon.2024.e29682</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Guo D, Zhou S, Liu R, et al. NEK2 contributes to radioresistance in esophageal squamous cell carcinoma by inducing protective autophagy via regulating TRIM21. Cancer Cell Int. 2024;24(1):179. DOI: 10.1186/s12935-024-03367-5</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Wen S, Liu Y, Yang M, et al. Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation. Oncol Rep. 2016;36(4):2193-9. DOI: 10.3892/or.2016.5009</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Xu H, Wen J, Yang J, et al. Tumor-microenvironment-on-a-chip: the construction and application. Cell Commun Signal. 2024;22(1):515. DOI: 10.1186/s12964-024-01884-4</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>McCrury M, Swafford K, Shuttleworth SL, et al. Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Mol Cancer Ther. 2024;23(3):316-329. DOI: 10.1158/1535-7163.MCT-23-0299</mixed-citation></ref></ref-list></back></article>
